CBLN1 and Leber congenital amaurosis: In line with in vivo findings, CER(d18:1/18:1) treatment attenuated LCA-induced cell death while upregulating LXRβ and SULT2A1 (Fig. S12b−S12e), silencing LXRβ abolished the protective effects of CER(d18:1/18:1) against LCA in HepG2 cells (Fig. S12f−S12h).